Pfizer Ltd (PFIZER)
₹4,623.60
Mkt cap
₹21,152 Cr
P/E ratio
27.90
P/B
5.03
Div yield
1.62%
ROE
18.00%
ROCE
24.10%
EPS (TTM)
₹165.72
Book value
₹919
52W range
4,405–5,767
Sector
Healthcare
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−19.82% from high₹4,624
₹4,405+4.96% from low₹5,767
Current
₹4,623.60
Prev close
₹4,633.10
Day
−0.21%
Price performance
1D
−0.21%
1W
+1.00%
1M
+3.65%
3M
−2.32%
6M
−0.77%
1Y
−13.77%
YTD
−5.39%
Financials
FRevenue, profit & margin
P/E ratio
27.9×
PFIZER is 18% below the sector median of 34.0×
PFIZER27.9×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 573 | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | |
| Expenses | 391 | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | |
| Operating Profit | 182 | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | |
| OPM % | 32% | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% | |
| Other Income | 12 | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 | |
| Interest | 3 | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | |
| Depreciation | 26 | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | |
| Profit before tax | 165 | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | |
| Tax % | 21% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | |
| Net Profit | 130 | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | |
| EPS in Rs | 28.34 | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
28 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.09% · closed higher next day 18 of last 54
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 11 Aug '23◦ | 28 Oct '23◦ | 9 Feb '24◦ | 17 May '24◦ | 29 Jul '24◦ | 28 Oct '24◦ | 31 Jan '25◦ | 20 May '25◦ | 13 Aug '25◦ | 28 Nov '25◦ | 9 Feb '26◦ | 12 May '26◦ |
| Earnings day | −3.04% | +0.19% | −0.00% | +1.65% | +3.99% | −1.37% | +0.54% | +0.59% | +4.33% | −0.17% | +4.13% | −2.38% |
| +1 day | −2.56% | −0.05% | −0.73% | −0.41% | +5.27% | −3.25% | −0.75% | +3.83% | +12.91% | +0.39% | +9.10% | −0.95% |
| +5 days | −1.53% | −0.61% | +5.61% | +3.43% | +7.92% | +0.96% | −3.97% | +11.34% | +10.99% | −0.19% | +6.06% | −0.81% |
| +15 days | −2.47% | +2.53% | +5.30% | +11.99% | +11.32% | −0.81% | −9.76% | +16.69% | +0.71% | +2.37% | +2.15% | −6.42% |
| +30 days | −2.74% | +4.09% | −3.59% | +4.08% | +14.01% | −4.64% | −10.18% | +15.46% | −3.95% | −2.37% | −1.15% | −5.61% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 75 Per Share | 75.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
Sas of Jun 202663.92%Promoter
Promoters63.92%
FIIs1.65%1.16
DIIs17.80%0.91
Public16.62%0.26
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Pfizer | ₹4,623.60 | 27.88 | 21,152 | 1.62% | 200 | −2.64% | 629 | +6.31% | 24.06% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bse
Concall transcripts7
Announcements5
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30, 2026. 20 Jul - Board meets July 28, 2026 to approve Q1 FY27 unaudited results; trading window closed until 48 hours after release.Response To Clarification Sought By BSE Limited. 17 Jul - Pfizer says Premarin Vaginal Cream is temporarily discontinued in India due to supply constraints; under 1% revenue impact.Clarification sought from Pfizer Ltd 17 Jul - Exchange has sought clarification from Pfizer Ltd on July 17, 2026, with reference to news appeared in https://www.thehindubusinessline.com/ dated July 17, 2026 quoting "Pfizer suspends …Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Jul - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026Letter To Shareholders Providing The Weblink To Access The Annual Report For Financial Year 2025-26. 7 Jul - Pfizer posts FY26 annual report link; 75th AGM on July 28, 2026; final dividend Rs.75 per share.